Share this article
Share this article
ResearchAndMarkets.com s offering.
The North America digital pathology market size is expected to reach USD 593.9 million by 2028. The market is expected to expand at a CAGR of 6.5% from 2021 to 2028.
The market is predominantly driven by the growing prevalence of chronic diseases such as cancer. As a consequence of the high prevalence of cancer, pathologists require data that facilitate personalizing therapy for patients. Hence, digital pathology is progressively being selected by pathologists as it has various benefits including accelerated diagnosis rate, diagnostic accuracy, and offers therapeutic recommendations to improve patient outcomes.
The growing number of collaborative agreements to develop as well as expedite the adoption of digital pathology in cancer diagnostics serves as a key growth factor contributing to the market. The use of artificial intelligence in digital pathology has gained momentum in the past years. The increasin
North America Digital Pathology Market Report 2021: Increasing Prevalence of Chronic Diseases / Higher Cost-Efficiency / Rapid Technological Advancement
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
North America $593 9 Million Digital Pathology Market Size, Share & Trends Analysis & Forecast to 2028
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights
News provided by
Share this article
SAN DIEGO, Feb. 25, 2021 /PRNewswire/
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced recent company highlights and financial results for the fourth quarter and full year ended December 31, 2020. Over the last several months we achieved key clinical milestones, which provided the momentum for our successful raise of over $100 million. Together, these events have enabled us to accelerate the execution of our clinical programs and expand our pipeline to other relevant cancer indications, said Dr. Mark Erlander, chief executive officer of Cardiff Oncology. Data from our lead KRAS-mutated metastatic color